How Supreme Court decision will affect FDA, biopharma. Under the radar cancer targets. Takeaways from a Q&A with Howard Chang.

Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors